Shahan Momjian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shahan Momjian has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Philippe Bijlenga
Division of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, University of Geneva, 1205 Geneva, Switzerland
19 shared publications - Christel Voize
Department of Oncology, Lausanne University Hospital, Swiss Cancer Center Leman, Lausanne, Switzerland
18 shared publications - Darel Martinez Bedoya
Brain Tumor and Immune Cell Engineering Laboratory, AGORA Cancer Research Center, Lausanne, Switzerland
18 shared publications - Denis Migliorini
Department of Oncology, University Hospital of Geneva, Geneva, Switzerland
18 shared publications - Eliana Marinari
Brain Tumor and Immune Cell Engineering Laboratory, AGORA Cancer Research Center, Lausanne, Switzerland
18 shared publications - Karl Schaller
Division of Neurosurgery, Department of Clinical Neuroscience, Geneva University Hospitals, 1205 Geneva, Switzerland
18 shared publications
Latest Publications
- Open Access
How well does electrical source imaging reconstruct neural time series? Evidence from simultaneous scalp and intracranial EEG recordings
Electrical source imaging (ESI) estimates neural activity from scalp EEG, but its ability to reconstruct the temporal dynamics of spontaneous brain activity beyond source localization remains unclear. This is assessed using simultaneous high-density EEG and intracranial EEG (iEEG) recordings during spontaneous activity in 34 patients with drug-resistant focal epilepsy. Four ESI approaches (three distributed source models and one beamformer) are applied to estimate neural activity, which is then projected onto iEEG electrode locations to generate virtual iEEG signals for comparison with measured recordings. Reconstruction fidelity is quantified using Pearson correlations between actual and virtual iEEG signals, while spatial accuracy is assessed through peak localization error and spatial deviation derived from point-spread and cross-talk functions. Analyses are performed in broadband and delta, theta, alpha, and beta bands. Temporal reconstruction remains limited, with the highest estimated correlation reaching 0.126, localization errors of approximately 3 cm, and substantial spatial leakage. Reconstruction quality decreases with electrode depth and increasing frequency, while improving with higher epileptic spike rates. No single method is optimal across all metrics, although beamforming shows the weakest temporal reconstruction. These findings indicate that ESI only partially captures spontaneous intracranial dynamics and define spatial and temporal constraints for interpreting EEG- based source reconstructions.
Open AccessHow well does electrical source imaging reconstruct neural time series? Evidence from simultaneous scalp and intracranial EEG recordings
Electrical source imaging (ESI) estimates neural activity from scalp EEG, but its ability to reconstruct the temporal dynamics of spontaneous brain activity beyond source localization remains unclear. This is assessed using simultaneous high-density EEG and intracranial EEG (iEEG) recordings during spontaneous activity in 34 patients with drug-resistant focal epilepsy. Four ESI approaches (three distributed source models and one beamformer) are applied to estimate neural activity, which is then projected onto iEEG electrode locations to generate virtual iEEG signals for comparison with measured recordings. Reconstruction fidelity is quantified using Pearson correlations between actual and virtual iEEG signals, while spatial accuracy is assessed through peak localization error and spatial deviation derived from point-spread and cross-talk functions. Analyses are performed in broadband and delta, theta, alpha, and beta bands. Temporal reconstruction remains limited, with the highest estimated correlation reaching 0.126, localization errors of approximately 3 cm, and substantial spatial leakage. Reconstruction quality decreases with electrode depth and increasing frequency, while improving with higher epileptic spike rates. No single method is optimal across all metrics, although beamforming shows the weakest temporal reconstruction. These findings indicate that ESI only partially captures spontaneous intracranial dynamics and define spatial and temporal constraints for interpreting EEG- based source reconstructions.
- Open Access
- 8 July 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Plasma oxytocin, early predictor of transient postoperative arginine vasopressin deficiency
Context: Arginine vasopressin deficiency (AVP-D) is a well-known complication of transsphenoidal pituitary surgery (TPS) that is difficult to predict due to the lack of specific biomarkers. While oxytocin (OXT) and copeptin were previously suggested as possible biomarkers, there is, to date, no study that compared those two markers in the prediction of post-TPS AVP-D. Objectives: To compare plasma OXT and copeptin levels among patients operated by TPS presenting with AVP-D and those remaining normonatremic. To establish OXT and copeptin cutoff values for the prediction of post-TPS AVP-D. Design and Patients: Both OXT and copeptin levels in the blood of 74 consecutive patients subjected to TPS were measured. OXT and copeptin values were then compared between patients developing AVP-D and patients remaining normonatremic. Setting: Neurosurgical department of a University Hospital. Main outcome measures: Blood levels of copeptin and OXT were measured before, one day after and 3 months after TPS. Results: Patients developing AVP-D showed significantly lower levels of OXT in blood, both before and immediately after TPS, and significantly lower levels of copeptin only after TPS. We identified a preoperative cutoff value for OXT of 69 pg/ml (sensitivity: 90% ; specificity: 66% ; AUC: 0.76+/-0.06 (p = 0.0089)) for the prediction of AVP-D. No such significant cutoff values were identified for preoperative copeptin. Of note, OXT, but not copeptin, levels were still significantly lower at 3 months after TPS in AVP-D patients. Conclusions: These results show for the first time that OXT is superior to copeptin for the preoperative prediction of postoperative AVP-D, acting as a preoperative marker of posterior “pituitary reserve”.
- 8 July 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open AccessPlasma oxytocin, early predictor of transient postoperative arginine vasopressin deficiency
Context: Arginine vasopressin deficiency (AVP-D) is a well-known complication of transsphenoidal pituitary surgery (TPS) that is difficult to predict due to the lack of specific biomarkers. While oxytocin (OXT) and copeptin were previously suggested as possible biomarkers, there is, to date, no study that compared those two markers in the prediction of post-TPS AVP-D. Objectives: To compare plasma OXT and copeptin levels among patients operated by TPS presenting with AVP-D and those remaining normonatremic. To establish OXT and copeptin cutoff values for the prediction of post-TPS AVP-D. Design and Patients: Both OXT and copeptin levels in the blood of 74 consecutive patients subjected to TPS were measured. OXT and copeptin values were then compared between patients developing AVP-D and patients remaining normonatremic. Setting: Neurosurgical department of a University Hospital. Main outcome measures: Blood levels of copeptin and OXT were measured before, one day after and 3 months after TPS. Results: Patients developing AVP-D showed significantly lower levels of OXT in blood, both before and immediately after TPS, and significantly lower levels of copeptin only after TPS. We identified a preoperative cutoff value for OXT of 69 pg/ml (sensitivity: 90% ; specificity: 66% ; AUC: 0.76+/-0.06 (p = 0.0089)) for the prediction of AVP-D. No such significant cutoff values were identified for preoperative copeptin. Of note, OXT, but not copeptin, levels were still significantly lower at 3 months after TPS in AVP-D patients. Conclusions: These results show for the first time that OXT is superior to copeptin for the preoperative prediction of postoperative AVP-D, acting as a preoperative marker of posterior “pituitary reserve”.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Bystander killing by 471_28z CAR-T cells depends on soluble mediators and does not affect macrophages
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Bystander killing by 471_28z CAR-T cells depends on soluble mediators and does not affect macrophages
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Expression of effector/memory and activation/exhaustion markers by CAR-T cells in pre- vs. post-thawing samples
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Expression of effector/memory and activation/exhaustion markers by CAR-T cells in pre- vs. post-thawing samples
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
In vivo anti-tumor activity of anti-PTPRZ1 CAR-T cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
In vivo anti-tumor activity of anti-PTPRZ1 CAR-T cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Bystander killing by anti-PTPRZ1 CAR-T cells using additional tumor cell lines and scFv
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Bystander killing by anti-PTPRZ1 CAR-T cells using additional tumor cell lines and scFv
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
PTPRZ1 expression at the mRNA level according to different GBM clinicopathologic features
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
PTPRZ1 expression at the mRNA level according to different GBM clinicopathologic features
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Primer pairs for CAR-T cell phenotyping by qPCR
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Primer pairs for CAR-T cell phenotyping by qPCR
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Use of Jurkat triple reporter cells to assess CAR tonic signaling and specificity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Use of Jurkat triple reporter cells to assess CAR tonic signaling and specificity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Anti-PTPRZ1 CAR-T cell effector function after incubation with the Ge1302_PTPRZ1-KI cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma
Anti-PTPRZ1 CAR-T cell effector function after incubation with the Ge1302_PTPRZ1-KI cells